GE Healthcare to expand Rapiscan access through new acquisition

GE Healthcare is to commercialise the pharmacological stress agent Rapiscan outside the US, Canada and Mexico through a new acquisition.

The company has agreed a deal to purchase Rapidscan Pharma Solutions, which has exclusive rights to produce and sell the Rapiscan brand in international territories.

Rapiscan is approved by the European Medicines Agency as a selective coronary vasodilator, used as a stress agent for radionuclide myocardial perfusion imaging in adult patients and for the diagnosis of coronary artery disease.

GE Healthcare already distributes Rapiscan in the UK and Germany and will maintain existing supplier and distributor networks created by Rapidscan Pharma Solutions as it rolls the product out on a global basis.

This agreement will complement Astellas' commercial distribution of Rapiscan in the US, Canada and Mexico.

Emmanuel Ligner, general manager of core imaging for GE Healthcare's life sciences business, said: "As Rapiscan is a market leader in Germany and Austria but largely unavailable in many other regions, we will use GE Healthcare's industry scale to drive improved access to this diagnostic tool for patients worldwide."

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.